Biological reprogramming in acquired resistance to endocrine therapy of breast cancer.
about
Estrogen receptor alpha gene amplification in breast cancer: 25 years of debateThe Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancerVAV3 mediates resistance to breast cancer endocrine therapy.Evolutionary strategy for systemic therapy of metastatic breast cancer: balancing response with suppression of resistanceClinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studiesSteroid hormone modulation of RET through two estrogen responsive enhancers in breast cancer.A cluster of noncoding RNAs activates the ESR1 locus during breast cancer adaptation.The Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer.Robust identification of transcriptional regulatory networks using a Gibbs sampler on outlier sum statisticMolecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells.Identifying protein interaction subnetworks by a bagging Markov random field-based method.Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer.The interaction between ER and NFκB in resistance to endocrine therapy.Improving Pathological Assessment of Breast Cancer by Employing Array-Based Transcriptome Analysis.Genome-wide activity of unliganded estrogen receptor-α in breast cancer cells.Endocrine resistance in breast cancer.Understanding tamoxifen adherence in women with breast cancer: A qualitative study.Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitEndocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer.Small molecule metabolite extraction strategy for improving LC/MS detection of cancer cell metabolome.Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.More than just side-effects: The role of clinical and psychosocial factors in non-adherence to tamoxifen.UBASH3B promotes tamoxifen resistance and could be negatively regulated by ESR1.Deregulation of FGFR1 and CDK6 oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the MIR9 family.Endocrine therapy-resistant breast cancer model cells are inhibited by soybean glyceollin I through Eleanor non-coding RNATNFAIP3 is required for FGFR1 activation-promoted proliferation and tumorigenesis of premalignant DCIS.COM human mammary epithelial cells
P2860
Q24273274-2E3AB20A-4FBB-4945-B10A-EEED62000F85Q30978083-C7E321F7-B674-40D6-9404-B6197CE88857Q33585930-B30747F0-DC0E-43FA-B7B9-05B6BB79D0E5Q33827037-0BA646EC-6050-4069-B0FF-3E8C2327C585Q34650211-6F4E55F5-84CD-412B-9772-F842EAC48E4EQ35016088-4B7373B2-1943-4C09-A0AF-94E9FDA0E05FQ35200153-1607F7A1-C7B0-4E9E-A50F-2F0D56F829A3Q35574894-69ADA771-9567-4CDE-8996-C43C3F2AC845Q35684410-FF43C4DD-07D5-487D-AC20-768E858F77B3Q36105793-6F2B284E-E6D1-4F83-89D5-62549881ABB4Q36400882-AEA9BC57-14EF-42EC-A681-55FA78F80CE4Q36559266-BC0A43BC-0B16-4EC8-986D-9C872531000BQ36782224-29FB5FB2-0759-4A64-90AA-9A8CFE39E605Q36924406-EC70A59E-46A3-4F3B-A78E-AB292B5D8088Q37214212-CAC3B89B-A70D-4B6F-8C6E-4976B8B08829Q37687555-27769088-74DE-4CA9-A32A-FBBBEB059A0AQ38163573-59542F62-33D7-4B18-9436-D2187274CC81Q38399176-360CF32A-26F5-4C77-BC40-44BD1E74CB37Q39172020-1E289FFC-939B-4375-9216-81C03D223EA7Q39185424-2BA7E83C-E31C-4BCE-9534-892EDDBF5061Q39566899-07F63052-BA0B-4A10-BD88-C52FE438B2E4Q41134570-29E24648-FE24-4128-BB12-A3DAB65C225EQ47681960-66B6CB62-2560-4539-AD48-47BE1F232229Q52680490-F62EF882-3FC0-4ACD-B7F0-D79F925C495AQ54570256-6FBE31A1-AD27-4A43-A2F7-ECD6AA2D6CD2Q57472758-5C1F7785-4B85-4B67-A34A-EC8A0D182A0DQ58777990-6BA15FFB-7D65-4E71-9081-AF826C98D0D1
P2860
Biological reprogramming in acquired resistance to endocrine therapy of breast cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Biological reprogramming in acquired resistance to endocrine therapy of breast cancer.
@en
Biological reprogramming in acquired resistance to endocrine therapy of breast cancer.
@nl
type
label
Biological reprogramming in acquired resistance to endocrine therapy of breast cancer.
@en
Biological reprogramming in acquired resistance to endocrine therapy of breast cancer.
@nl
prefLabel
Biological reprogramming in acquired resistance to endocrine therapy of breast cancer.
@en
Biological reprogramming in acquired resistance to endocrine therapy of breast cancer.
@nl
P2093
P2860
P50
P356
P1433
P1476
Biological reprogramming in acquired resistance to endocrine therapy of breast cancer
@en
P2093
J Serra-Musach
M A Pujana
M Méndez-Pertuz
R L Beijersbergen
P2860
P2888
P304
P356
10.1038/ONC.2010.333
P407
P577
2010-08-16T00:00:00Z